CASI Pharma (CASI) - Analyst Ratings

CASI Pharma (CASI) – Analyst Ratings

May 13, 2022 06:07 AM Oppenheimer Reiterates Outperform Rating, $6 Price Target on CASI Pharmaceuticals (CASI) Following Company's Q1 Update
Mar 29, 2022 06:30 AM Oppenheimer Reiterates CASI Pharmaceuticals (CASI) at Outperform, "CASI is an Underappreciated Story Among Small-cap Biotechs"
Dec 1, 2021 05:00 PM
Aug 13, 2021 09:21 AM
May 17, 2021 04:22 PM
Apr 26, 2021 05:29 AM
Oct 23, 2020 07:01 AM
Apr 17, 2017 07:48 AM
Sep 21, 2016 05:27 PM
Jun 23, 2015 07:20 AM
Sep 18, 2014 10:37 AM